439239-90-4,MFCD18633238
Catalog No.:AA00DB3R

439239-90-4 | Lasmiditan

This product is typically in stock,please click "Inquire" below or
contact us at [email protected] for pricing and availability information.
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00DB3R
Chemical Name:
Lasmiditan
CAS Number:
439239-90-4
Molecular Formula:
C19H18F3N3O2
Molecular Weight:
377.3603
MDL Number:
MFCD18633238
SMILES:
CN1CCC(CC1)C(=O)c1cccc(n1)NC(=O)c1c(F)cc(cc1F)F
Properties
Computed Properties
 
Complexity:
530  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
27  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
4  
XLogP3:
2.8  

Literature

Title: Emerging treatment for chronic migraine and refractory chronic migraine.

Journal: Expert opinion on emerging drugs 20120901

Title: The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.

Journal: The journal of headache and pain 20120601

Title: Defining and refining 5-HT receptor targets for migraine.

Journal: The Lancet. Neurology 20120501

Title: Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.

Journal: The Lancet. Neurology 20120501

Title: Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment.

Journal: Cephalalgia : an international journal of headache 20110701

Title: Treatment of migraine: update on new therapies.

Journal: Current opinion in neurology 20110601

Title: Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.

Journal: Cephalalgia : an international journal of headache 20101001

Title: Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.

Journal: Cephalalgia : an international journal of headache 20101001

Title: Molecule of the month. Lasmiditan hydrochloride.

Journal: Drug news & perspectives 20100901

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 439239-90-4
Tags:439239-90-4 Molecular Formula|439239-90-4 MDL|439239-90-4 SMILES|439239-90-4 Lasmiditan
Catalog No.: AA00DB3R
439239-90-4,MFCD18633238
439239-90-4 | Lasmiditan
This product is typically in stock,please click "Inquire" below or contact us at [email protected]for pricing and availability information.
Inquire
Technical Information
Catalog Number: AA00DB3R
Chemical Name: Lasmiditan
CAS Number: 439239-90-4
Molecular Formula: C19H18F3N3O2
Molecular Weight: 377.3603
MDL Number: MFCD18633238
SMILES: CN1CCC(CC1)C(=O)c1cccc(n1)NC(=O)c1c(F)cc(cc1F)F
Properties
Complexity: 530  
Covalently-Bonded Unit Count: 1  
Heavy Atom Count: 27  
Hydrogen Bond Acceptor Count: 7  
Hydrogen Bond Donor Count: 1  
Rotatable Bond Count: 4  
XLogP3: 2.8  
Literature fold

Title: Emerging treatment for chronic migraine and refractory chronic migraine.

Journal: Expert opinion on emerging drugs20120901

Title: The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.

Journal: The journal of headache and pain20120601

Title: Defining and refining 5-HT receptor targets for migraine.

Journal: The Lancet. Neurology20120501

Title: Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.

Journal: The Lancet. Neurology20120501

Title: Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment.

Journal: Cephalalgia : an international journal of headache20110701

Title: Treatment of migraine: update on new therapies.

Journal: Current opinion in neurology20110601

Title: Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.

Journal: Cephalalgia : an international journal of headache20101001

Title: Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial.

Journal: Cephalalgia : an international journal of headache20101001

Title: Molecule of the month. Lasmiditan hydrochloride.

Journal: Drug news & perspectives20100901

Building Blocks More >
5128-44-9
5128-44-9
7,4'-Di-O-methylapigenin
AA00DB7W | MFCD00017446
50536-72-6
50536-72-6
3H-Benzo[e]indole-2-carboxylic acid
AA00DBD2 | MFCD02320869
4728-12-5
4728-12-5
(2,2-Dimethyl-1,3-dioxan-5-yl)methanol
AA00DBI8 | MFCD04119722
51516-70-2
51516-70-2
5-Amino-1-(4-fluorophenyl)-1h-pyrazole-4-carbonitrile
AA00DBP5 | MFCD00102729
51285-60-0
51285-60-0
4,4'-Dibromo-2,2'-bithiophene
AA00DBXS | MFCD00508561
55170-74-6
55170-74-6
5-Methylhex-5-enoic acid
AA00DC4J | MFCD02259906
55242-55-2
55242-55-2
PROPENTOFYLLINE
AA00DCBB | MFCD00133785
562803-76-3
562803-76-3
(3-((1H-Pyrazol-1-yl)methyl)phenyl)methanamine
AA00DCNB | MFCD08572164
479500-37-3
479500-37-3
1-(5-methyl-1H-pyrazol-3-yl)methanamine
AA00DCRD | MFCD08059768
Submit
© 2017 AA BLOCKS, INC. All rights reserved.